Eli Lilly and Company

Lilly Industries, Inc.

Michael Brunavs

Peter Thaddeus Gallagher

Colin W Smith

William M Owton

Colin P Dell

Erik James Hembre, Ii

Jai P Singh

Kevin Matthew Gardinier

Terence Alan Hicks

Helen Jane Szekeres

David Joseph Garmene

David R Dobson

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein '-----' is absent or is optionally a bond; q is 1 or 2; Ris independently selected from hydrogen, &#x2014;C-Calkyl, halo, hydroxy, &#x2014;C-Chaloalkyl, &#x2014;C-Calkoxy, cyano, &#x2014;O&#x2014;C-Ccycloalkyl, and &#x2014;OC-Chaloalkyl; Ris selected from the group consisting of hydrogen, &#x2014;C-Calkyl, hydroxy, &#x2014;C-Calkoxy, cyano, &#x2014;C-Chaloalkyl, &#x2014;OC-Chaloalkyl, and halo; Ris selected from the group consisting of hydrogen, &#x2014;C-Calkyl, &#x2014;C-Chaloalkyl, &#x2014;C-CalkylOH, &#x2014;C-Ccycloalkyl, &#x2014;CHC-Ccycloalkyl, &#x2014;C-Calkyl-O&#x2014;C-Calkyl, &#x2014;C(O)C-Calkyl, &#x2014;C(O)C-Chaloalkyl, &#x2014;CH-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C-Calkyl, and &#x2014;C-Chaloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases. 

5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists

Pharmaceutical compounds of the formula ##STR1## in which n is 0, 1 or 2 and R.sup.1 is attached at any of the positions 7, 8, 9 or 10, and each R.sup.1 is halo, carboxy, trifluoromethyl, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, hydroxy-C.sub.1-4 alkyl, hydroxy-C.sub.1-4 alkoxy, nitrogen-containing heterocyclyl, nitro, trifluoromethoxy, --COOR.sup.5 where R.sup.5 is an ester group, --COR.sup.6, --CONR.sup.6 R.sup.7 or --NR.sup.6 R.sup.7 where R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl;

Pharmaceutical compounds

Pharmaceutical compounds of the formula ##STR1## in which n is 0, 1 or 2 and R.sup.1 is attached at any of the positions 7, 8, 9 or 10, and each R.sup.1 is halo, carboxy, trifluoromethyl, hydroxy, C.sub.1 -4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, hydroxy-C.sub.1-4 alkyl, hydroxy-C.sub.1-4 alkoxy, nitrogen-containing heterocyclyl, nitro, trifluoromethoxy, --COOR.sup.5 where R.sup.5 is an alkyl group, --COR.sup.6, --CONR.sup.6 R.sup.7 or --NR.sup.6 R.sup.7 where R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl;

5,6-dihydronaphtho [1,2-b]pyrans and their use as pharmaceutical

Pharmaceutical compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, hydroxyl, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, acyloxy, --O-glucoside, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkoxy;

Methods of treating an immune disease, cell proliferation, restenosis and vascular smooth muscle cells using the pharmaceutical compounds of the formula ##STR1## in which R.sup.2 is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted, or R.sup.2 is furanyl optionally substituted with C.sub.1-4 alkyl; and salts thereof.

Methods of using dihydropyrans

This invention provides a method of treating diabetic complications in mammals which comprises the administration of a compound of the Formula I: ##STR1## in which n, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are variables.

Growing community of inventors

Frimley, United Kingdom

Michael Brunavs